For research use only. Not for therapeutic Use.
TQS is a α7 nicotinic acetylcholine receptor (nAChR) positive allosteric modulator. TQS can be used for the research of neuroinflammatory pain[1].
TQS (1 or 4 mg/kg; i.p.) reduces the expression of LPS-induced IκB mRNA, CD11b mRNA and regulates microglial morphological changes in the hippocampus[1].
| Catalog Number | I010921 |
| CAS Number | 353483-92-8 |
| Synonyms | 4-naphthalen-1-yl-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide |
| Molecular Formula | C22H20N2O2S |
| Purity | ≥95% |
| InChI | InChI=1S/C22H20N2O2S/c23-27(25,26)15-11-12-21-20(13-15)17-8-4-10-19(17)22(24-21)18-9-3-6-14-5-1-2-7-16(14)18/h1-9,11-13,17,19,22,24H,10H2,(H2,23,25,26) |
| InChIKey | SIZWDJIHABLBSP-UHFFFAOYSA-N |
| SMILES | C1C=CC2C1C(NC3=C2C=C(C=C3)S(=O)(=O)N)C4=CC=CC5=CC=CC=C54 |
| Reference | [1]. Abbas M, et al. The α7 nicotinic acetylcholine receptor positive allosteric modulator attenuates lipopolysaccharide-induced activation of hippocampal IκB and CD11b gene expression in mice. Drug Discov Ther. 2017;11(4):206-211. |
